Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.
endomyocardial biopsy
DPD scintigraphy with Perugini grade 2-3 where variant amyloidosis is ruled out due to genetic testing.
Informed oral and written consent
AL amyloidosis (light-chain amyloidosis).
Myelomatosis
Waldenström macroglobulinemia
Patients > 18 years
Steen Hvitfeldt Poulsen
Lead sponsor
Aarhus University Hospital Skejby
Sponsor institution
Novo Nordisk A/S
Collaborator